. Author manuscript; available in PMC: 2009 Oct 1.

Published in final edited form as: Expert Rev Anti Infect Ther. 2008 Dec;6(6):805–824. doi: 10.1586/14787210.6.6.805

Table 2.

MICs (mg/l) of, and susceptibility to, cefepime, ceftazidime and imipenem among clinical populations of Gram-negative Enterobacteriaceae

Organism	Region	Site of infection	Year(s) of collection	MIC (mg/l)^*									Ref.
				Cefepime			Ceftazidime			Imipenem
				MIC₅₀	MIC₉₀	S (%)	MIC₅₀	MIC₉₀	S (%)	MIC₅₀	MIC₉₀	S (%)
Escherichia coli	North America	Mixture	2007	≤0.12	0.25	95.9	0.25	1	96.6	0.12	0.25	100	[138]
		BSI, RT	1998-2004	≤0.12	≤0.12	99.6	≤2	≤2	98.6	≤0.5	≤0.5	100	[40]
		UTI	1998	≤0.12	≤0.12	100	0.25	0.5	99.9	0.12	0.25	100	[139]
	Latin America	BSI	1997-2000	≤0.12	0.25	97.1	0.25	0.5	95.6	0.12	0.25	100	[140]
	Europe	Mixture	1997-1998	≤0.12	≤0.12	99.2	≤0.12	0.25	98.1	0.25	0.5	100	[141]
	America and Europe	Mixture	2005-2006	≤0.12	0.25	96.0	≤1	≤1	95.0	≤0.12	0.25	100	[31]
	Asia-Pacific	UTI	1998-1999	≤0.12	0.25	98.6	0.25	0.5	96.7	0.12	0.25	100	[142]
E. coli ESBL+	North America	Mixture	1998-2003	0.25	4	93.8	8	>16	60.6	≤0.5	≤0.5	100	[35]
E. coli ESBL+	America and Europe	Mixture	2005-2006	16	>16	39.6	16	>16	39.6	0.25	0.5	100	[31]
Klebsiella spp.	North America	Mixture	2007	≤0.12	16	89.9	0.25	>16	81.7	0.25	2	90.9	[138]
		BSI, RT	1998-2004	≤0.12	0.25	99.0	≤2	≤2	95.1	≤0.5	≤0.5	99.7	[40]
		RT	2000	≤0.12	0.25	99.5	0.25	8	NR	≤0.06	0.25	87.8	[143]
		UTI	1998	≤0.12	0.25	99.4	0.25	0.5	95.8	0.25	0.5	100	[139]
	Latin America	BSI	1997-2000	0.25	>16	74.8	1	>16	64.0	0.25	0.5	99.8	[140]
	Latin America	RT	1997-2000	<0.12	>16	76.1	0.5	>16	63.1	0.25	0.5	99.6	[144]
	Europe	Mixture	1997-1998	<0.12	8		≤0.12	>16	81.3	0.5	1	99.9	[141]
	America and Europe	Mixture	2005-2006	≤0.12	>16	86.5	≤1	>16	81.7	0.25	0.5	97.2	[31]
	Asia-Pacific	UTI	1998-1999	≤0.12	4	98.6	0.25	>16	87.3	0.25	0.5	100	[142]
Klebsiella spp. ESBL+	North America	Mixture	1998-2003	1	8	92.5	>16	>16	36.9	≤0.5	≤0.5	99.3	[35]
Klebsiella spp. ESBL+	America and Europe	Mixture	2005-2006	8	>16	51.4	>16	>16	33.0	0.25	0.5	99.3	[31]
Enterobacter spp.	North America	Mixture	2007	≤0.12	2	95.3	0.25	>16	78.8	0.5	2	97.6	[138]
	North America	BSI, RT	1998-2004	≤0.12	2	99.3	≤1	>16	78.4	≤0.5	1	100	[40]
	Latin America	BSI	1997-2000	≤0.12	8	91.5	0.5	>16	68.4	0.5	1	99.7	[140]
	Latin America	RT	1997-2000	0.12	>16	61.2	0.5	>16	63.4	0.5	2	100	[144]
	Europe	Mixture	1997-1998	≤0.12	4	95.2	0.25	>16	78.4	0.5	2	99.6	[141]
	America and Europe	Mixture	2005-2006	≤0.12	4	93.4	≤1	>16	71.1	0.5	2	98.4	[31]
	Asia-Pacific	UTI	1998-1999	0.25	8	95.3	4	>16	51.2	0.5	2	100	[142]
Proteus mirabilis	North America	Mixture	2007	≤0.12	≤0.12	100	≤0.12	≤0.12	100	1	2	99.2	[138]
	Europe	Mixture	1997-1998	≤0.12	0.50	96.3	≤0.12	1	95.3	1	2	99.5	[141]
	America and Europe	Mixture	2005-2006	≤0.12	0.25	94.3	≤1	≤1	98.3	1	2	99.8	[31]
Providencia spp.	Europe and Australia	Mixture	1999-2000	0.03	1	99.0	NR	NR	NR	2	8	98.0	[36]
Morganella morganii	Europe and Australia	Mixture	1999-2000	0.03	2	100	NR	NR	NR	4	8	92.0	[36]
Salmonella spp.	America and Europe	Mixture	2005-2006	≤0.12	≤0.12	100	≤1	≤1	98.1	0.25	0.5	100	[31]
Citrobacter spp.	America and Europe	Mixture	2005-2006	≤0.12	1	98.3	≤1	>16	75.9	0.5	1	99.6	[31]
Serratia spp.	America and Europe	Mixture	2005-2006	≤0.12	0.5	97.5	≤1	2	95.2	1	2	99.8	[31]

Results were interpreted according to Clinical and Laboratory Standards Institute criteria.

BSI: Bloodstream infection; ESBL+: Extended-spectrum β-lactamase-producing organisms; NR: Not reported; RT: Respiratory tract infection; S: Susceptibility; UTI: Urinary tract infection.